Get the Stockscreener App
0.5996
3.38%
+0.0196
Pre-market:
.6223
0.0227
+3.79%
COMPANY PROFILE
Name180 Life Sciences Corp
SectorHealthcare (1499)
IndustryBiotechnology (867)
Web
Phone650 507 0669
Employee0
AddressBuilding 4, 3000 El Camino Real Suite 200, Palo Alto, null, United States (94306)
News
Price History
Option Chain
Financials
Insider Trading
Why ATNF Down?
Discussions
Forecast
Stock Split
Dividend History
180 Life Sciences Corp Stock (ATNF) Latest News
Benzinga
Why Nikola Shares Are Trading Higher By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Why Rubicon Technologies Shares Are Trading Lower By Over 7%; Here Are 20 Stocks Moving Premarket
GlobeNewswire Inc.
180 Life Sciences Corp. Announces Closing of $3 Million Public Offering
Benzinga
Why Krispy Kreme Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
GlobeNewswire Inc.
180 Life Sciences Corp. Announces Pricing of $3 Million Public Offering
Benzinga
Why AppLovin Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarket
Benzinga
Why EMCORE Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket
GlobeNewswire Inc.
180 Life Sciences Announces an Agreement for a Clinical Pharmacology Study Testing a New Formulation of CBD for Enhanced Oral Uptake
GlobeNewswire Inc.
180 Life Sciences Corp. Announces Closing of $3 Million Registered Direct Offering and Concurrent Private Placement
About 180 Life Sciences Corp
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Cap:
|
Volume (24h):